PLA2G4A: A Potent Enzyme Implicated in Cell Signaling, Inflammation and Neurodegeneration

Target Name: PLA2G4A

NCBI ID: G5321

PLA2G4A

PLA2G4A: A Potent Enzyme Implicated in Cell Signaling, Inflammation and Neurodegeneration

PLA2G4A, also known as phospholipase A2 group IVA, is a protein that is expressed in various cell types throughout the body. It is a potent enzyme that is involved in the process of phospholipase A2, which is a critical step in the release of phospholipids from cells.

PLA2G4A is a transcript variant of the gene PLA2G4, which encodes a protein with 155 amino acid residues. The gene is located on chromosome 14q21 and has been implicated in various cellular processes, including cell signaling, inflammation, and neurodegeneration.

PLA2G4A is a member of the PLA2G4 gene family, which includes several related proteins that are involved in the same set of cellular processes. These proteins include PLA2G4B, PLA2G4B3, PLA2G4B4, PLA2G4B5, and PLA2G4B6. All of these proteins share a similar catalytic mechanism and are involved in the hydrolysis of phospholipids.

PLA2G4A is expressed in various cell types, including neurons, astrocytes, and endothelial cells. It is highly expressed in the brain and has been implicated in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

PLA2G4A has also been shown to be involved in inflammation and immune responses. It has been shown to play a role in the regulation of T cell responses and has been implicated in the development of autoimmune diseases.

PLA2G4A is also a potential drug target and may be a promising new therapeutic agent for various diseases. For example, PLA2G4A has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease, and may be a target for therapeutic intervention. Additionally, PLA2G4A has been shown to be involved in the regulation of T cell responses and has been implicated in the development of autoimmune diseases. As such, PLA2G4A may be a promising new therapeutic target for various autoimmune diseases.

In conclusion, PLA2G4A is a protein that is involved in the process of phospholipase A2 and is expressed in various cell types throughout the body. It is a potent enzyme that has been implicated in various cellular processes, including cell signaling, inflammation, and neurodegeneration. PLA2G4A is also a member of the PLA2G4 gene family and has been shown to play a role in the regulation of T cell responses and the development of autoimmune diseases. As such, PLA2G4A may be a promising new therapeutic target for various diseases.

Protein Name: Phospholipase A2 Group IVA

Functions: Has primarily calcium-dependent phospholipase and lysophospholipase activities, with a major role in membrane lipid remodeling and biosynthesis of lipid mediators of the inflammatory response (PubMed:7794891, PubMed:8619991, PubMed:8702602, PubMed:9425121, PubMed:10358058, PubMed:14709560, PubMed:16617059, PubMed:17472963, PubMed:27642067, PubMed:18451993). Plays an important role in embryo implantation and parturition through its ability to trigger prostanoid production (By similarity). Preferentially hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) (PubMed:7794891, PubMed:8619991, PubMed:9425121, PubMed:10358058, PubMed:17472963, PubMed:18451993). Selectively hydrolyzes sn-2 arachidonoyl group from membrane phospholipids, providing the precursor for eicosanoid biosynthesis via the cyclooxygenase pathway (PubMed:18451993, PubMed:7794891, PubMed:9425121, PubMed:10358058, PubMed:17472963). In an alternative pathway of eicosanoid biosynthesis, hydrolyzes sn-2 fatty acyl chain of eicosanoid lysophopholipids to release free bioactive eicosanoids (PubMed:27642067). Hydrolyzes the ester bond of the fatty acyl group attached at sn-1 position of phospholipids (phospholipase A1 activity) only if an ether linkage rather than an ester linkage is present at the sn-2 position. This hydrolysis is not stereospecific (PubMed:7794891). Has calcium-independent phospholipase A2 and lysophospholipase activities in the presence of phosphoinositides (PubMed:12672805). Has O-acyltransferase activity. Catalyzes the transfer of fatty acyl chains from phospholipids to a primary hydroxyl group of glycerol (sn-1 or sn-3), potentially contributing to monoacylglycerol synthesis (PubMed:7794891)

The "PLA2G4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLA2G4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets